Important Notice to Geron Corporation Shareholders
New York, April 3, 2025 – The Gross Law Firm, a leading securities fraud law firm, issues this notice to all investors who purchased Geron Corporation (NASDAQ: GERN) securities between January 1, 2023, and March 31, 2025. The firm is investigating potential securities fraud and is encouraging all affected shareholders to contact the firm.
Background on Geron Corporation
Geron Corporation is a biotechnology company focused on the development and commercialization of therapeutics for aging and age-related diseases. The company’s lead product candidate, Imetelstat, is an investigational therapy for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Investigation Details
The Gross Law Firm’s investigation focuses on potential securities laws violations by Geron Corporation and its executives. Specifically, the firm is investigating whether the company made false and misleading statements regarding the safety and efficacy of Imetelstat. The investigation comes after a series of clinical trial setbacks and disappointing financial results.
Impact on Shareholders
As a result of this investigation, Geron Corporation shareholders may have legal claims. If the company’s statements were materially misleading, shareholders may be able to recover their losses through a securities class action lawsuit. The Gross Law Firm encourages all affected shareholders to contact the firm to discuss their legal rights and potential remedies.
Worldwide Implications
Beyond the immediate impact on Geron Corporation shareholders, this investigation raises broader concerns for the biotech industry as a whole. The failure of Imetelstat to meet expectations and the subsequent investigation could deter investors from investing in similar companies. Additionally, the investigation could lead to increased scrutiny of clinical trial data and regulatory oversight in the biotech sector.
Conclusion
The Gross Law Firm’s investigation into Geron Corporation is a reminder of the importance of transparency and accuracy in the biotech industry. Shareholders rely on truthful information when making investment decisions, and companies that fail to provide this information can face serious legal consequences. If you are a Geron Corporation shareholder and believe you may have a claim, contact The Gross Law Firm for a free consultation.
- Geron Corporation shareholders encouraged to contact The Gross Law Firm
- Investigation focuses on potential securities fraud
- Broader concerns for the biotech industry
